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transition in hepatocellular carcinoma by
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Gang Shen1†, Ye Lin2†, Xuewei Yang3, Jing Zhang1, Zhe Xu4 and Hongyun Jia5*Abstract
Background: Metastasis is responsible for the rapid recurrence and poor survival of malignancies.
Epithelial-mesenchymal transition (EMT) has a critical role in metastasis. Increasing evidence indicates that EMT
can be regulated by microRNAs (miRNAs). The aim of this study was to investigate the role of miR-26b in modulating
epithelial-mesenchymal transition (EMT) in hepatocellular carcinoma (HCC), as well as to identify its underlying
mechanism of action.
Methods: The expression level of miR-26b was assessed in multiple HCC cell lines (HepG2, MHCC97H, Hep3B,
MHCC97L, HCCC9810, BEL-7402, Huh7 and QGY-7703), as well as in liver tissue from patients with HCC. Follow-up
studies examined the effects of a miR-26b mimic (increased expression) and a miR-26b inhibitor (decreased
expression) on markers of EMT, wound healing and cell migration. The molecular target of miR-26b was also identified
using a computer algorithm and confirmed experimentally.
Results: MiR-26b expression was decreased in HCC cell lines and was inversely correlated with the grade of HCC.
Increased expression of miR-26b inhibited the migration and invasiveness of HCC cell lines, which was accompanied
by decreased expression of the epithelial marker E-cadherin and increased expression of the mesenchymal marker
vimentin, at both the mRNA and protein expression levels. A binding site for miR-26b was theoretically identified in
the 3′UTR of USP9X. Further studies revealed that overexpression of miR-26b repressed the endogenous level of
USP9X protein expression. Overexpression of miR-26b also repressed Smad4 expression, whereas its inhibition elevated
Smad4 expression.
Conclusions: Taken together, our results indicate that miR-26b were inhibited in HCC. In HCC cell lines, miR-26b
targeted the 3′UTR of USP9X, which in turn affects EMT through Smad4 and the TGF-β signaling pathway. Our
analysis of clinical HCC samples verifies that miR-26b also targets USP9X expression to inhibit the EMT of hepatocytes.
Thus, miR-26b may have some effects on the EMT of HCC cells.
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Hepatocellular carcinoma (HCC) is a common and ag-
gressive cancer, with an increasing incidence globally,
especially in China [1]. Despite technical advances and
improved surgical treatment, the rate of tumor recur-
rence and metastasis after curative resection remains high
[2,3]. Exploring the molecular mechanisms underlying the* Correspondence: hongyun_jia@163.com
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may provide new therapeutic targets, leading to improve-
ments in the long-term survival of patients with HCC [4].
Although the genetic events responsible for HCC initi-
ation and progression are not clear, they involve at least
three carcinogenic pathways: the p53, NF-κB and trans-
forming growth factor (TGF-β) signaling pathways [5-7].
The TGF-β signaling pathway is particularly pertinent
to the current study, as it is known to play a central
role in tumorigenesis and tumor progression by regu-
lating many critical cellular processes, including celld. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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sition (EMT) [7]. Furthermore, TGF-β has been shown to
have a central role in the growth of hepatocytes [8]. With
regard to the progression of HCC, it has previously been
shown in HCC cell lines, such as Hep3B, HepG2, PLC/
PRF5, that TGF-β signaling triggers EMT [9], character-
ized by lower E-cadherin expression and high vimentin
expression in vitro [10]. There is also convincing evidence
that TGF-β signaling can induce EMT in mouse hepato-
cytes in vitro [11]. Subsequent studies revealed the mech-
anism to be the result of TGF-β-induced activation of the
SNAIL transcription factor, a key mediator of EMT, and
repression of epithelial markers, such as E-cadherin [12].
The Smad protein family is known to play a key role in
the TGF-β signaling, particularly Smad4, the ubiquitina-
tion of which is a key regulatory step in TGF-β signaling
[13]. Indeed, loss of inactivation of Smad4 has been linked
with multiple cancers, including pancreatic, colorectal,
and gastrointestinal cancers [14-16].
Protein ubiquitination is a reversible, post-translational
modification that regulates various aspects of cellular phy-
siology, including protein degradation and cell signaling
[17]. Deubiquitinating enzymes (DUBs) are ubiquitin-
specific proteases that can cleave ubiquitin from its sub-
strate [18]. Among approximately 100 DUBs encoded by
the human genome, the ubiquitin-specific peptidase 9,
X-linked (USP9X/FAM), is implicated in multiple physio-
logical pathways [19]. USP9X has been shown to regulate
multiple cellular functions, and increased expression of
USP9X in tumors is significantly associated with poor
prognosis for patients with multiple myeloma [20]. Nu-
merous targets of USP9X have been identified so far, in-
cluding AF-6, β -catenin, NUAK1, MARK4, ErbB2, EFA6,
Smad4, Mcl1, ASK1 and survivin [21].
Recently, microRNA (miRNA) mimics and anti-sense
microRNAs have been focused on as potential thera-
peutics for HCC due to their stability and predominant
uptake by the liver [22]. MiRNAs bind to the 3′ untrans-
lated region (UTR) to suppress translation of target ge-
nes [23]. An increasing body of evidence indicates that
miR-26b is downregulated in breast cancer [24], naso-
pharyngeal carcinoma [25], colorectal cancer [26] and in
hepatocellular carcinoma [27]. miR-26b has also been
associated with hepatocellular carcinoma development
and worst outcome after liver cancer therapy [28,29].
However, to date, the role of miR-26b in hepatocellular
carcinoma tumorigenesis and metastasis is incompletely
understood.
The goal of the current study was to investigate the
role of miR-26b in HCC. We found that the expression of
miR-26b was decreased in HCC cells and tissues from
HCC patients with advanced grades of disease. Mimicry of
miR-26b in Huh7 and Hep3B cells resulted in diminished
proliferation, migration and invasiveness, accompanied bya low expression level of USP9X. Further, we identified
USP9X as a target of miR-26b, which was confirmed by
luciferase analysis, Western blotting examination. Our
study provides evidence that miR-26b acts as tumor




Liver samples collected from patients with HCC and
control liver samples were collected for research pur-
poses, with the patient’s prior consent and approval from
the Second Affiliated Hospital of Guangzhou Medical
University and the Guangzhou Women and Children’s
Medical Center.
Cell culture
The following human HCC cell lines were studied: HepG2,
MHCC97H, Hep3B, MHCC97L, HCCC9810, BEL-7402,
Huh7 and QGY-7703. All cells were grown in DMEM
medium (Invitrogen, Carlsbad, CA, USA) supplemented
with 10% fetal bovine serum (HyClone, Logan, Utah, USA)
and 1% penicillin/streptomycin.
Manipulation of miR-26b expression levels
The miR-26b mimics, negative control (micrON™ miRNA
Mimic Negative Controls and micrOFF™ miRNA Inhibitor
Negtive Controls) and miR-26b inhibitor were purchased
from RiboBio (Guangzhou, Guangdong, China). The final
concentrations of transfection is 20 nM.
Construction of USP9X plasmids
The region of the human USP9X 3′-UTR, from 1041 to
1486 were generated by PCR amplification from DNA
isolated from HepG2 cells. The amplified fragment was
then cloned into the pEGFP-C1 (Clontech, Mountain
View, CA, USA) and pGL3 vector (Promega, Madison,
Wisconsin, USA). The primers selected were as follows:
USP9X -3′UTR-GFP-up, 5′ CCGCTCGAGCCAGTG
ACGTGGAAGTCATC 3′; USP9X -3′UTR-GFP-dn,
5′ CGGGGTACCCACCACAGGACAAAAAGTTCTTC
3′; USP9X -3′UTR-luc-up, 5′ CGGGGTACCCCAGTG
ACGTGGAAGTCATC 3′; and USP9X -3′UTR-luc-dn, 5′
CCGCTCGAGCACCACAGGACAAAAAGTTCTTC 3′.
Cell transfections
Transfection of the plasmids, miRNA and miRNA in-
hibitor was performed using Lipofectamine 2000 (Invi-
trogen, Carlsbad, USA) according to the manufacturer’s
instructions.
Western blotting
Cells were harvested in sampling buffer (62.5 mmol/L
Tris-HCl [pH 6.8], 10% glycerol, 2% SDS) and heated for
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was determined by the Bradford assay using a com-
mercial kit (Bio-Rad, Berkeley, CA, USA ). Equal quan-
tities of protein were separated by electrophoresis on
12% SDS/polyacrylamide gels and transferred onto poly-
vinylidene difluoride membranes (Roche, Indianapolis,
Indiana, USA). The membranes were then probed with
rabbit primary antibodies against USP9X(#5751S), E-
cadherin(#9835S), Vimentin(#3877P) and GFP(#2955S)
(Cell Signaling Technology, Danvers, Massachusetts,
USA). The expression level of the target protein was de-
termined with horseradish peroxidase-conjugated anti-
rabbit/anti-mouse IgG (#31212/ #31160) and enhanced
chemiluminescence (Pierce, Rockford, Illinois, USA), ac-
cording to the manufacturer’s protocol. The membranes
were stripped and reprobed with an anti-β-actin mouse
monoclonal antibody (BOSTER, Wuhan, Hubei, China) to
serve as a loading control.
RNA extraction and real-time quantitative PCR
Total miRNA from cultured cells and fresh surgical HCC
tissues was extracted using the mirVana miRNA Isolation
Kit (# AM1561, Ambion, Austin, Texas, USA), according
to the manufacturer’s protocol. Complimentary DNA was
synthesized from 5 ng of total RNA using the TaqMan
miRNA reverse transcription kit (Applied Biosystems,
Foster City, California, USA). The expression level of
miR-26b was quantified using a miRNA-specific TaqMan
MiRNA Assay Kit (Applied Biosystems), using an Applied
Biosystems 7500 Sequence Detection system. The expres-
sion level of miRNA was defined based on the threshold
cycle (Ct), and relative expression levels were calculated
using the 2-ΔΔCt method, using the expression level of the
U6 small nuclear RNA as a reference gene.
Cell migration assay
The migration assay was performed using a transwell
chamber, consisting of 8 mm membrane filter inserts
(Corning, New York, USA) coated with Matrigel (BD
Biosciences, California, USA). Briefly, cells were trypsi-
nized and suspended in serum-free medium. Next, 1.5 ×
105 cells were added to the upper chamber, and the lower
chamber was filled with medium containing 10% FBS.
After 36 h incubation, cells that had invaded the lower
chamber were fixed with 4% paraformaldehyde, stained
with hematoxylin, and counted using a microscope.
Wound healing assay
The wound healing assay was performed using HepG2
and Huh7 cells. Cells were trypsinized and seeded in equal
numbers into 6-well tissue culture plates, and allowed to
grow until confluent (approximately 24 h). Following se-
rum starvation for 24 h, an artificial homogenous wound
(‘scratch’) was created onto the cell monolayer with asterile 100 μL tip. After scratching, the cells were washed
with serum-free medium, complete media was added, and
microscopic images (20× magnification) of the cells were
collected at 0, 12, and 24 h.
3D morphogenesis assay
Twenty-four-well dishes were coated with Growth Fac-
tor Reduced Matrigel (BD Biosciences, California, USA),
and covered with growth medium supplemented with
2% Matrigel. Cells were trypsinized and seeded at a
density of 104 cells/well. The medium was replaced with
2% Matrigel every 3 to 4 days and microscopic images
(20× magnification) were captured at 2 day intervals for
2 to 3 weeks.
Dual luciferase reporter assay
Cells (3.5 × 104) were seeded in triplicate in 24-well
plates and allowed to settle over 24 h. Next, 100 ng of
pGL3-USP9X-3′UTR (wt/mut), or control-luciferase plas-
mid plus 1 ng of pRL-TK renilla plasmid (# E2810.
Promega, Madison, Wisconsin, USA) were transfected
into the cells using Lipofectamine 2000 (Invitrogen Co.,
Carlsbad, California, USA), according to the manufactu-
rer’s recommendations. Luciferase and renilla signals were
measured 48 h after transfection using the Dual Luciferase
Reporter Assay Kit (Promega, Madison, Wisconsin, USA),
according to the manufacturer’s protocol. Three inde-
pendent experiments were performed and the data are
presented as the mean ± SD.
Statistical analysis
A two-tailed Student’s t-test was used to evaluate the
statistical significance of the differences between two
groups of data in all pertinent experiments. A P-value
less than 0.05 was considered to be statistically signifi-
cant. All statistical analyses were performed using the
SPSS 13.0 (IBM) statistical software package.
Microscopy
The microscopy we have used as:
Zeiss Axio Imager A1——Zeiss, Oberkochen, Germany
Zeiss Axiovert 40c——Zeiss, Oberkochen, Germany
Axiovert 200——Zeis, Oberkochen, Germany
Results
MiR-26b downregulation correlates with progression of
human hepatocellular carcinoma
An increasing body of evidence indicates miR-26b is
downregulated in several cancers, including hepatocellu-
lar carcinoma. But its role in the tumorigenesis of HCC
remains poorly understood. In our early studies, the re-
sult of real-time PCR analysis showed that the expres-
sion level of miR-26b was markedly downregulated in all
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MHCC97H, BEL-7402, Huh7, HCCC-9810, Hep3B and
QGY-7703), in comparison with the expression levels
in normal liver tissue from three patients( P < 0.001)
(Figure 1). The clinical relevance of the downregulated
miR-26b was studied in twelve archived clinical HCC
samples, classified as grade I to IV according to the
WHO definitions. Our data show that miR-26b levels
downregulated in HCC tissues, compared with the normal
tissues( P < 0.001). Moreover, the expression of miR-26b is
negatively correlates with the severity and progression of
HCC. As shown in Figure 1, we can see that the miR-26b
expression still remained high in grade I and II tumors,
but became markedly lower in grade III and IV tumors.
Taken together these results indicate that miR-26b may be
an tumor inhibitor in the progression of human hepato-
cellular carcinoma.
MiR-26b suppresses the invasiveness of HCC cells
To investigate the biological function of miR-26b in
HCC cells, we used Huh7/Hep3B cell line with medium-
level of miR-26b expression for both knockdown and
overexpression modifications, by which subsequent func-
tional analyses could be performed comparatively among
miR-26b-overexpressing, -silenced, and NC control cells
that had the same parental genetic background. We trans-
fected the HCC cell lines Huh 7 and Hep3B with miR-26b
mimic oligonucleotides to increase the endogenous level
of miR-26b, or miR-26b complementary oligonucleotides
to decrease the levels of miR-26b (Figures 2A). The first
parameter we studied was the expression of genes related
to cell invasion. Western blotting and Real-time PCR ana-
lyses showed that the epithelial marker E-cadherin wasFigure 1 Downregulation of miR-26b in human HCC cell lines and tiss
human liver tissue (Normal), and HCC tissues at different WHO classification
cell lines: HepG2, MHCC97L, MHCC97H, Bel-7402, Huh7, HCCC-9810, Hep3B
Each bar represents the mean of three independent experiments. * P < 0.05
the normal tissues and the HCC tissues, the normal tissues and HCC cell linupregulated following transfection with the miR-26b mi-
mic, and decreased with oligonucleotides against miR-26b
(Figures 2B and C). On the other hand, that mesenchymal
marker vimentin was downregulated following transfec-
tion with the miR-26b mimic, and was increased by oligo-
nucleotides against miR-26b (Figures 2B and C).
Next, we assessed the effect of manipulating cellular
miR-26b levels on the migration of Huh 7 and Hep3B
cells using wound healing and cell migration assays. The
wound healing assay demonstrated that ectopic expres-
sion of miR-26b slowed down the migration of Huh 7
and Hep3B cells, while inhibiting endogenous miR-26b
dramatically accelerated migration (Figure 2D).
The cell migration assay showed that overexpression
of miR-26b reduced the number of migratory cells, while
inhibition of miR-26b increased the number of migra-
tory HCC cells (Figure 3A). Strikingly, in a 3D spheroid
invasion assay, decreased levels of miR-26b in HCC cells
were associated with morphologies typical of highly ag-
gressive and invasive cells, presenting more outward
projections compared with the control cells. Conversely,
elevated levels of miR-26b caused the cells to be immo-
tile and to display spheroid morphologies (Figure 3B).
What’ s more, an E-cadherin staining showed the corre-
sponding result (Additional file 1: Figure S1).
MiR-26b directly targets USP9X in HCC cells
It is known that Smad4 ubiquitination is a key regulatory
step in the TGF-β signaling pathway, and it was later
shown that the DUB USP9X was required for Smad ac-
tivity [30]. In mammalian cells and Xenopus embryos,
USP9X sustains both TGF-β and BMP signaling by deu-
biquitinating Smad4 and by counteracting the inhibitoryues. The relative expression level of miR-26b was examined in normal
s. The expression level of miR-26b was also compared in eight HCC
, and QGY-7703. All experiments were repeated at least three times.
. The average expression level of miR-26b were compared between
es.
Figure 2 Increased levels of miR-26b suppress mobolity and E-cadherin expression in HCC cell lines. (A) Real-time PCR analysis of
expression of miR-26b in indicated cells. U6 was used as a loading control. Error bars represent mean ± SD from three independent experiments.
(B) Western blotting analysis of USP9X, SMAD4, E-cadherin and vimentin expression in indicated cells. (C) Real-time PCR analysis of expression
of E-cadherin and vimentin in indicated cells. GAPDH was used as a loading control. Error bars represent mean ± SD from three independent
experiments. (D) A wound closure assay was used to assess the mobility of Huh7 and Hep3B cells treated with the empty vector, miR-26b mimic
or miR-26 inhibition (original magnification: ×20;).
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FAM (especially USP9x), a deubiquitinase acting as es-
sential and evolutionarily conserved component in TGF-
β signal pathway [32]. We analysis with the use of two
publicly available algorithms (TargetScan and miRanda)
revealed that USP9X is a theoretical target gene of miR-
26b (Figure 4A). Subsequent Western blotting and im-
munofluorescence staining results showed that miR-26b
mimicry dramatically decreased the expression level of
USP9X, and inhibition of miR-26b increased USP9X pro-
tein expression in HCC cells (Figure 2B and Figure 4B).
But the result of Real-time PCR showed that the mRNA
levels of USP9X remains unchanged after miR-26b ma-
nipulation( data not showed). While the effect of USP9X
on ubiquitination of Smad4 after miR-26b modulation as
shown in Additional file 2: Figure S2.
To determine whether the miR-26b-induced down-
regulation of USP9X was mediated through the 3′UTRcontaining the miR-26b binding site, we subcloned the
USP9X 3′UTR fragment into PEGFP-C1 and pGL3 dual
luciferase reporter vectors. As our Western blotting ana-
lysis showed, elevating the endogenous levels of miR-26b
only decreased expression of the GFP vector containing
the USP9X with 3′UTR, but had no effect on GFP-r-
tubulin expression (Figure 4B), suggesting that miR-26b
specifically affected the 3′UTR of USP9X. Furthermore,
western blotting and immunofluorescence staining re-
sults showed that the abundance of Smad4 was signi-
ficantly increased when miR-26b was suppressed, and
was decreased in the presence of elevated miR-26b ex-
pression (Figure 2B and 4C). Moreover, a consistent and
dose-dependent reduction in luciferase activity was ob-
served following miR-26b transfection in both Huh7 and
Hep3B cells, whereas the repressive effect of miR-26b on
the luciferase activity of USP9X 3′UTR was abolished by
miR-26b inhibition (Figure 4D), and point mutations in
Figure 3 Increased levels of miR-26b suppress EMT in HCC cell lines. (A) The invasive properties of HCC cells treated with the empty vector,
miR-26b mimic and miR-26b inhibitor were analyzed using a cell invasion assay in transwell chambers. Representatives images of cells that had
migrated into the lower chamber are shown (left panel; original magnification: ×400), and quantitative data are also presented (right panel). The
average number of cells per field of view from three different experiments are plotted. (B) The invasive properties of HCC cells treated with empty
vector, miR-26b mimic or miR-26b inhibitor were also performed using a 3D spheroid invasion assay. Representative images of cells after 8 days
in culture are shown (upper; original magnification:: ×200, bottom; original magnification:: ×400).
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3′-UTR abrogated the suppressive effect of USP9X
mediated by miR-26b (Figure 4E). Last but not the least,
real-time PCR result showed that the expression level
of SNAIL mRNA was significantly decreased in either
miR-26b orUSP9X siRNA over-expressed HCC cells
(Additional file 3: Figure S3). Collectively, these re-
sults demonstrate that miR-26b directly acts through
the 3′UTR of USP9X in HCC cells.
USP9X plays an important role in miR-26b suppressed
invasiveness of HCC cells
To further investigate the role of increased USP9X ex-
pression in cells with suppressed miR-26b levels and in-
creased invasiveness, the effects of USP9X without 3′
UTR and USP9X with 3′UTR were examined in cells
transfected with miR-26b mimics. The migration assay
showed that co-transfection of miR-26b and USP9X
without 3′UTR significantly improved the migration rate
of both Huh7 and Hep3B cells. However, the combin-
ation of USP9X with 3′UTR and miR-26b had no obvi-
ous effect on migration, compared to cells transfected
with miR-26b and vector (Figure 5A). Furthermore, cellstransfected with miR-26b-in and USP9X siRNA signi-
ficantly decreased the migration rate when compared
to cells transfected with miR-26b-in and scramble in
Huh7 (Additional file 4: Figure S4). Furthermore, we re-
introduced the USP9X siRNA into the miR-26b inhib-
bited HCC cancer cells. As shown in Additional file 5:
Figure S5, ectopic expression of USP9X siRNA increased
the expression levels of E-cadherin and decreased the ex-
pression levels of vimentin.
In order to confirm the link between miR-26b, USP9X
and EMT in HCC, we studied the expression level of
miR-26b, USP9X and E-cadherin in primary liver tumor
tissue from patients with HCC. For this analysis, five
freshly prepared normal human liver samples were com-
pared with nine samples from patients with HCC. As
shown in Figure 5B, miR-26b expression and E-cadherin
protein expression were markedly downregulated in HCC
tissue, but the expression level of USP9X was higher, com-
pared with normal human liver tissue. Furthermore, linear
regression analysis showed that miR-26b expression po-
sitively correlated with E-cadherin expression (r = 0.838,
P < 0.05), and negatively correlated with USP9X (r =–0.714,
P < 0.05).
Figure 4 (See legend on next page.)
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Figure 4 miR-26b downregulates USP9X expression via directly targeting the USP9X 3′UTR. (A) Sequence alignment of the 3′UTR in Hs
(human), Mm(mouse), Rn(rat), and Cf (dog) with miR-26b indicates that miR-26b targets USP9X expression. (B) Representative western blots of
GFP expression in Huh7 and Hep3B cells under the indicated experimental conditions. (C) Representative fluorescent microscope images of
Smad4 expression in Huh7 and Hep3B cells following treatment with the empty vector, miR-26b inhibitor and miR-26b mimic are shown. (D)
Luciferase activity assay of indicated cells transfected with the pGL3-USP9X-3′UTR reporter with increasing amounts (10, 50 ,100 nM) of miR-26b
mimic- or miR-26b inhibitor-oligonucleotides. (E) Luciferase assays on Huh7 or Hep3B HCC cells transfected with the pGL3 control reporter,
pGL3-USP9X-3′UTR reporter, or pGL3-USP9X-3′UTR-mu reporters and increasing amounts of miR-26b mimic oligonucleotides (10, 50 nM),
as indicated. Error bars represent mean 6 SD from three independent experiments. *P < 0.05.
Figure 5 miR-26b downregulates USP9X via directly targeting the USP9X 3′UTR. (A) Representative images of cells in the lower section of a
transwell chamber are shown to demonstrate the invasive properties of Huh7 and Hep3B cells when transfected with a mixed miR-26b and
USP9X vector, or a mixed miR-26b and USP9X-3′UTR (left panel). Quantitative analyses of migrated cells are also shown ( right panel); data are
plotted as the average number of cells per field of view from three different experiments (original magnification: ×400). (B) The relative expression
level of miR-26b is shown for five normal liver tissue samples (N), and nine HCC liver tissue samples (upper right panel). Below, the corresponding
expression levels of USP9X, E-cadherin and β-actin are shown in the same samples. Linear regression analyses of miR-26b expression with USP9X
and E-cadherin are also presented (right panel).
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The goal of the current study was to investigate the role
of miR-26b in EMT and the metastasis of HCC. During
EMT, polarized epithelial cells acquire a mesenchymal
phenotype; in the context of cancer, this transformation
is associated with tumor invasiveness, metastasis, and re-
sistance to chemotherapy [5,7,23,24]. A number of cyto-
kines and growth factors are known to be induced during
EMT, which amplifies the EMT program and promotes
cell migration. These factors include the cytokines TGF-β,
Wnt, Notch ligands, interleukin-like EMT-inducers [6],
hepatocyte growth factor [8], epidermal growth factor [30]
and platelet-derived growth factor [31].
The levels of transcription factors driving EMT are con-
trolled by miRNAs [33]. While miR-26a and miR-26b have
been reported can regulate the NF-κB, TGF-β signal path-
ways [34]. And miR-26b was downregulated in hepatic tu-
mors, as compared to paired noncancerous tissue [35].
Similarly, patients whose tumors had low miR-26 expres-
sion had a shorter survival time, although they were more
likely to respond to interferon-α than patients whose tu-
mors had high miR-26 expression [28]. Several studies
have confirmed that miR-26a and miR-26b are downregu-
lated in NPC (nasopharyngeal carcinoma) [36], CRC (colo-
rectal cancer) [37]. Mechanistically, miR-26 is thought to
be growth suppressive; it has been shown that miR-26b
acts through c-myc to block the G1/S transition [19].
The role of TGFβ in EMT, tumor invasiveness and
metastasis has been firmly established by in vitro and
in vivo studies [8,32]. Interestingly, TGF-β-induced acti-
vation of Smad complexes (particularly Smad3 and 4)
have been shown to play a crucial role during the induc-
tion of EMT [32-35]. Ubiquitination of Smad4 is known
to be a key regulatory step in the TGF-β signaling path-
way, leading to the identification of the DUB USP9X as
a required factor for Smad activity [30,32,37]. In mam-
malian cells and Xenopus embryos, USP9X sustains both
TGF-β and BMP signaling by deubiquitinating Smad4
and counteracting the inhibitory activity of Ecto/Tif1-c
[32]. Here, we identified USP9X as a novel target of
miR-26b, such that miR-26b interacted with the 3′-UTR
of USP9X to suppress its expression, with resultant effects
on Smad4 expression and the TGF-β signaling pathway.
There is usually an inverse relationship between the
expression level of a particular miRNA and its target
[31]. Our conclusion that USP9X is a novel target gene
of miR-26b is supported by several pieces of evidence:
(1) the 3′-UTR of both human and murine USP9X mRNA
contains a putative miR-26b binding site; (2) miR-26b sup-
presses the activity of a luciferase reporter gene fused with
the 3′-UTR of USP9X mRNA, which is dependent on
the miR-26b binding sequence; (3) miR-26b represses
the endogenous expression of human/murine USP9X
at both the mRNA and protein level. Our follow-upstudies indicated that the ability of miR-26b to inhibit
cancer cell invasion was mediated through its ability
to downregulate USP9X expression.
USP9X was previously reported to regulate Smad4 tran-
scriptional activity positively, thus we hypothesized that
decreased USP9X expression would attenuate Smad4
function and TGF-β responsiveness in HCC cell lines
[38]. Our data demonstrate that transfection with a miR-
26b mimic decreased Smad4 expression in both Huh7 and
Hep3B cells, while transfection of a miR-26b inhibitor up-
regulated Smad4 expression. These results suggest that
the effect of miR-26b on HCC cells may be mediated
through Smad4, with a resultant effect on the TGF-β sig-
naling pathway.
Conclusion
In conclusion, we have identified miR-26b as a tumor
suppressive miRNA in human HCC, which acts at least
in part through the repression of USP9X. Mechanistic-
ally, our data suggests a model in which miR-26b binds
to the 3′-UTR of USP9X to inhibit its expression. De-
creased USP9X expression leads to an attenuation of
Smad4 function and TGF-β responsiveness, inhibiting
the EMT and growth of HCC cells. Our data suggests
that miR-26b may play some roles in the EMT of HCC
cells, although future studies are required to confirm this.
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